Loading...
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...
Na minha lista:
| Udgivet i: | Mol Metab |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4354919/ https://ncbi.nlm.nih.gov/pubmed/25830098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2015.01.009 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|